Purchase this article with an account.
Mohammed Khan, Francis DeCroos, Philip Storey, Jerry Shields, Sunir Garg, Carol Shields; Safety and Efficacy of Anti-VEGF Therapy for Choroidal Neovascularization Overlying Choroidal Osteoma. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5885.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the safety and efficacy of intravitreal bevacizumab or ranibizumab therapy for treatment of choroidal neovascularization (CNV) associated with choroidal osteoma.
Retrospective, observational, consecutive case series of patients diagnosed with choroidal osteoma and CNV who were treated with intravitreal bevacizumab and/or ranibizumab, on the Retina or Oncology Services of the Wills Eye Hospital, Philadelphia, PA.
Six tumors in six eyes were treated with intravitreal anti-VEGF therapy. Mean tumor basal diameter was 8.9 mm (range 4.5 - 14 mm), with mean tumor thickness 1.2 mm (range 1.0 - 1.6 mm). A mean of 10 intravitreal injections were completed (median 9, range 3 - 19 injections), with regression of CNV and resolution of fluid on optical coherence tomography achieved in 5 of 6 (83%) cases. Two tumors required 1 session of photodynamic therapy (PDT) for control in addition to anti-VEGF therapy. Improvement or stability of visual acuity was observed in 5 of 6 eyes (83%, range 0 to 6 Snellen line improvement). Patients were followed over a mean period of 21 months (median 18, range 5 to 56 months), with one complication (traumatic cataract) observed.
Therapy with intravitreal bevacizumab and/or ranibizumab can be effective for CNV secondary to choroidal osteoma, with resolution of CNV and preservation of visual acuity.
This PDF is available to Subscribers Only